Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 18 h ago

Perspective Therapeutics, Inc.: Commodore Capital LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Commodore Capital LP amended its Schedule 13G filing on Perspective Therapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0001831942-26-000049. The amendment signals a change in the institutional investor's position in the radiopharmaceutical developer, though the filing headline did not disclose the revised share count or percentage. Schedule 13G amendments are typically watched for directional cues on institutional conviction in small-cap biotech names. Investors will look to the full filing for the updated ownership percentage and any change in voting authority. Perspective Therapeutics remains the focal company, with Commodore Capital's revised stake the key data point to track.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Perspective Therapeutics, Inc., Commodore Capital LP